A landmark study published in the prestigious medical journal JAMA Neurology has unveiled a significant, previously underappreciated connection between frontotemporal dementia (FTD) and epilepsy. By analyzing one of the largest and most comprehensive datasets of its kind, researchers from the University of Eastern Finland and the University of Oulu have demonstrated that epileptic seizures are far more prevalent in FTD patients than clinical literature previously suggested. This discovery not only challenges existing diagnostic frameworks for memory disorders but also underscores a critical need for clinicians to prioritize the monitoring and treatment of seizures in individuals living with FTD.

The research project, which was coordinated by Neurocenter Finland, represents a massive collaborative effort to bridge the gap in our understanding of how neurodegenerative conditions interact with the brain’s electrical activity. While the association between Alzheimer’s disease and epilepsy has been recognized for some time, the clinical relationship between FTD—a diverse group of disorders characterized by the progressive degeneration of the frontal and temporal lobes—and seizure activity has remained largely obscured. By scrutinizing over a decade of medical records, the researchers have finally brought this critical health intersection into the light.

Epilepsy as a Precursor to FTD Diagnosis

The scope of the investigation was vast, drawing on patient data from the university hospitals of Kuopio and Oulu spanning the years 2010 to 2021. From an initial pool of 12,490 medical records, the team identified 245 patients diagnosed with FTD and 1,326 patients diagnosed with Alzheimer’s disease. To ensure the findings were statistically robust, the researchers compared these cohorts against a group of healthy control subjects.

One of the most striking findings of the study is the temporal relationship between the onset of epilepsy and the eventual diagnosis of dementia. According to the research, epilepsy did not merely manifest in the late stages of FTD; in some instances, it appeared as long as a decade before a patient received a formal dementia diagnosis. This suggests that the occurrence of seizures might serve as an early, albeit subtle, clinical marker that could potentially assist in earlier identification of the disease process.

"Our results show that epilepsy is considerably more common among those with FTD than those with Alzheimer’s disease or in healthy controls," explains Doctoral Researcher Annemari Kilpeläinen, the first author of the research article and a medical specialist in neurology. Kilpeläinen highlights that the prevalence of epilepsy was not just a sporadic occurrence but a consistent feature across all stages of the disease progression monitored in the study. "It is noteworthy that epilepsy occurred in some patients with FTD already ten years before their dementia diagnosis, and it was more common in all the examined stages of the disease than previous international studies have reported," she adds.

The researchers assessed the prevalence of epilepsy at multiple intervals, ranging from ten years before the dementia diagnosis to five years afterward. The data revealed a clear upward trajectory: the prevalence of epilepsy in FTD patients increased steadily over time, reaching approximately 11% five years post-diagnosis. To validate these findings, the team also analyzed the use of anti-epileptic medications, which were found to be significantly more common in the FTD cohort, further reinforcing the reliability of the clinical diagnoses of epilepsy identified in the medical records.

The Challenge of Diagnosis and the Path Forward

The clinical reality of managing patients with FTD is fraught with complexity, not least because the behavioral and cognitive symptoms of the dementia itself can frequently mirror the manifestations of epileptic seizures. This clinical overlap often leads to a phenomenon of underdiagnosis, where the seizures are either missed entirely or misattributed to the psychiatric or behavioral changes associated with FTD.

This oversight has tangible consequences for patient care. Untreated epilepsy in the context of neurodegeneration can lead to a more rapid decline in cognitive and physical function, significantly diminishing a patient’s quality of life. The researchers argue that by failing to identify and treat these seizures, the medical community may be missing a vital opportunity to stabilize patients and mitigate some of the most disruptive aspects of their condition.

"Identifying epilepsy is important because its treatment can improve patients’ functional capacity and quality of life," notes Associate Professor Eino Solje, the project’s principal investigator and Director of the UEF Brain Research Unit. Beyond the immediate implications for clinical practice, the discovery opens up profound new avenues for scientific inquiry. The researchers are now prompted to investigate whether FTD and epilepsy share common pathophysiological mechanisms. Specifically, they are questioning whether some of the hallmark symptoms of FTD—such as personality changes, executive dysfunction, and language impairment—could be partially caused by underlying alterations in the brain’s electrical systems, rather than just the structural atrophy typically associated with the disease.

This shift in perspective could redefine the clinical approach to FTD, moving from a model of purely supportive care to one that actively addresses the electrophysiological health of the brain. If specific FTD symptoms are indeed exacerbated or caused by electrical instability, then targeted anti-epileptic interventions could become a standard component of future therapeutic strategies.

A Multidisciplinary Research Paradigm

The significance of these findings is bolstered by the structure of the research project itself, which is noted for its exceptional scale and multidisciplinary approach. By combining real-world patient data with unique, high-fidelity health registers, the research team was able to conduct an analysis that is rarely possible in smaller, more limited studies.

The project represents a deep collaboration between the University of Oulu and the University of Eastern Finland, but its reach extends beyond traditional medical research. By integrating experts from various fields, including medicine and law, the project team ensured a comprehensive review of the patient data, maintaining rigorous ethical and analytical standards throughout the study.

Both the Kuopio University Hospital and the Oulu University Hospital play vital roles in this research ecosystem. They are established members of the European Reference Network EpiCARE, an international consortium dedicated to the treatment and research of rare and complex epilepsies. Their participation in EpiCARE ensures that the findings from this study are not only relevant within a Finnish context but are also positioned within a broader, international framework of clinical excellence.

As the medical community digests these results, the message is clear: the relationship between frontotemporal dementia and epilepsy is far more intricate than previously acknowledged. For clinicians on the front lines of dementia care, this study serves as a critical call to action. By maintaining a higher index of suspicion for epileptic activity in FTD patients, and by integrating comprehensive neurological monitoring into the diagnostic process, doctors may be able to offer more effective, personalized care. The research from the University of Eastern Finland and the University of Oulu provides the evidentiary foundation for this change, marking a significant step forward in the quest to better understand, diagnose, and treat the multifaceted challenges of frontotemporal dementia.